JAK/STAT/SOCS信号通路在HBV相关肝脏疾病中的作用

彭玉娟; 游晶; 李静; 唐光俊

doi:10.3969/j.issn.1001-5256.2021.06.045

JAK/STAT/SOCS信号通路在HBV相关肝脏疾病中的作用

DOI: 10.3969/j.issn.1001-5256.2021.06.045

彭玉娟¹,
游晶^1, ,,
李静²,
唐光俊¹

1.
昆明医科大学第一附属医院感染性疾病和肝病科, 昆明 650032
2.
昆明医科大学公共卫生学院, 昆明 650500

基金项目:

国家自然科学基金 (81760111);

国家自然科学基金 (81760617)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：彭玉娟负责文献阅读及综述撰写；李静、唐光俊负责提供意见；游晶负责课题设计拟定写作思路，指导撰写、修改文章并最后定稿。

详细信息

作者简介:
彭玉娟(1991—)，女，主要从事肝病临床基础研究

通信作者:
游晶，jingyoukm@126.com

中图分类号: R512.62
计量
- 文章访问数: 600
- HTML全文浏览量: 144
- PDF下载量: 52
- 被引次数: 0
出版历程
- 收稿日期: 2020-10-29
- 录用日期: 2020-11-25
- 出版日期: 2021-06-20

Role of the JAK/STAT/SOCS signaling pathway in hepatitis B virus-related liver diseases

1.
Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, China
2.
School of Public Health, Kunming Medical University, Kunming 650500, China

摘要

摘要: JAK/STAT/SOCS信号通路可介导多种细胞因子参与炎症、肿瘤及自身免疫性疾病过程；其在HBV感染相关肝病中也有着重要作用。回顾了JAK-STAT和SOCS的结构及信号通路调节过程；并重点阐述了二者在HBV相关慢性乙型肝炎、肝硬化、肝衰竭及肝癌发生发展过程中的作用研究进展。最终分析表明JAK/STAT/SOCS信号通路在HBV相关肝病中存在失调，并参与了疾病的发生、发展过程，甚至对疾病的治疗及预后产生影响。
- 乙型肝炎病毒 /
- 肝疾病 /
- 信号传导
Abstract: The JAK/STAT/SOCS signaling pathway can mediate a variety of cytokines involved in inflammation, tumor, and autoimmune diseases and it also plays an important role in hepatitis B virus (HBV) infection-related liver diseases. This article briefly reviews the structure and signal pathway regulation of JAK-STAT and SOCS and elaborates on their role in the development and progression of HBV-related chronic hepatitis B, liver cirrhosis, liver failure, and hepatocellular carcinoma. The final analysis shows that the JAK/STAT/SOCS signaling pathway is dysregulated in HBV-related liver disease and is involved in the development and progression of the disease, and it may even influence the treatment and prognosis of the disease.
- Hepatitis B virus /
- Liver Diseases /
- Signal Transduction

HTML全文

参考文献(48)

[1]	WHO. Global hepatitis report, 2017[EB/OL].[2019-11-06]. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.
[2]	LIU J, LIANG W, JING W, et al. Countdown to 2030: Eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3): 230-238. DOI: 10.2471/BLT.18.219469.
[3]	SEIF F, KHOSHMIRSAFA M, AAZAMI H, et al. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells[J]. Cell Commun Signal, 2017, 15(1): 23. DOI: 10.1186/s12964-017-0177-y.
[4]	BOUSOIK E, MONTAZERI ALIABADI H. "Do We Know Jack" About JAK? A closer look at JAK/STAT signaling pathway[J]. Front Oncol, 2018, 8: 287. DOI: 10.3389/fonc.2018.00287.
[5]	NABAVI SM, AHMED T, NAWAZ M, et al. Targeting STATs in neuroinflammation: The road less traveled![J]. Pharmacol Res, 2019, 141: 73-84. DOI: 10.1016/j.phrs.2018.12.004.
[6]	LIM CP, CAO X. Structure, function, and regulation of STAT proteins[J]. Mol Biosyst, 2006, 2(11): 536-550. DOI: 10.1039/b606246f.
[7]	DURHAM GA, WILLIAMS J, NASIM MT, et al. Targeting SOCS proteins to control JAK-STAT signalling in disease[J]. Trends Pharmacol Sci, 2019, 40(5): 298-308. DOI: 10.1016/j.tips.2019.03.001.
[8]	MORRIS R, KERSHAW NJ, BABON JJ. The molecular details of cytokine signaling via the JAK/STAT pathway[J]. Protein Sci, 2018, 27(12): 1984-2009. DOI: 10.1002/pro.3519.
[9]	YIN Y, LIU W, DAI Y. SOCS3 and its role in associated diseases[J]. Hum Immunol, 2015, 76(10): 775-780. DOI: 10.1016/j.humimm.2015.09.037.
[10]	DEES C, PÖTTER S, ZHANG Y, et al. TGF-β-induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis[J]. J Clin Invest, 2020, 130(5): 2347-2363. DOI: 10.1172/JCI122462.
[11]	SADLER AJ, WILLIAMS BR. Interferon-inducible antiviral effectors[J]. Nat Rev Immunol, 2008, 8(7): 559-568. DOI: 10.1038/nri2314.
[12]	YU Y, WAN P, CAO Y, et al. Hepatitis B virus e antigen activates the suppressor of cytokine signaling 2 to repress interferon action[J]. Sci Rep, 2017, 7(1): 1729. DOI: 10.1038/s41598-017-01773-6.
[13]	MITRA B, WANG J, KIM ES, et al. Hepatitis B virus precore protein p22 inhibits alpha interferon signaling by blocking STAT nuclear translocation[J]. J Virol, 2019, 93(13): e00196-19. DOI: 10.1128/JVI.00196-19.
[14]	CHANG Z, WANG Y, ZHOU X, et al. STAT3 roles in viral infection: Antiviral or proviral?[J]. Future Virol, 2018, 13(8): 557-574. DOI: 10.2217/fvl-2018-0033.
[15]	ZANG M, LI Y, HE H, et al. IL-23 production of liver inflammatory macrophages to damaged hepatocytes promotes hepatocellular carcinoma development after chronic hepatitis B virus infection[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(12): 3759-3770. DOI: 10.1016/j.bbadis.2018.10.004.
[16]	ZHAO X, SUN L, MU T, et al. An HBV-encoded miRNA activates innate immunity to restrict HBV replication[J]. J Mol Cell Biol, 2020, 12(4): 263-276. DOI: 10.1093/jmcb/mjz104.
[17]	WU S, CHEN X, TANG Y, et al. Delivery of Tapasin-modified CTL epitope peptide via cytoplasmic transduction peptide induces CTLs by JAK/STAT signaling pathway in vivo[J]. Acta Biochim Biophys Sin (Shanghai), 2018, 50(2): 181-190. DOI: 10.1093/abbs/gmx133.
[18]	HOAN NX, van TONG H, GIANG DP, et al. SOCS3 genetic variants and promoter hypermethylation in patients with chronic hepatitis B[J]. Oncotarget, 2017, 8(10): 17127-17139. DOI: 10.18632/oncotarget.15083.
[19]	ZHANG P, LI F, LI N, et al. Genetic variations of SOCS1 are associated with chronic hepatitis B virus infection[J]. Hum Immunol, 2014, 75(8): 709-714. DOI: 10.1016/j.humimm.2014.04.010.
[20]	TANG LY, HELLER M, MENG Z, et al. Transforming growth factor-β (TGF-β) directly activates the JAK1-STAT3 axis to induce hepatic fibrosis in coordination with the SMAD pathway[J]. J Biol Chem, 2017, 292(10): 4302-4312. DOI: 10.1074/jbc.M116.773085.
[21]	GU YJ, SUN WY, ZHANG S, et al. Targeted blockade of JAK/STAT3 signaling inhibits proliferation, migration and collagen production as well as inducing the apoptosis of hepatic stellate cells[J]. Int J Mol Med, 2016, 38(3): 903-911. DOI: 10.3892/ijmm.2016.2692.
[22]	ZHAO J, QI YF, YU YR. STAT3: A key regulator in liver fibrosis[J]. Ann Hepatol, 2021, 21: 100224. DOI: 10.1016/j.aohep.2020.06.010.
[23]	MAIR M, BLAAS L, ÖSTERREICHER CH, et al. JAK-STAT signaling in hepatic fibrosis[J]. Front Biosci (Landmark Ed), 2011, 16: 2794-2811. DOI: 10.2741/3886.
[24]	ZHANG W, NIU M, YAN K, et al. Stat3 pathway correlates with the roles of leptin in mouse liver fibrosis and sterol regulatory element binding protein-1c expression of rat hepatic stellate cells[J]. Int J Biochem Cell Biol, 2013, 45(3): 736-744. DOI: 10.1016/j.biocel.2012.12.019.
[25]	MARTÍ-RODRIGO A, ALEGRE F, MORAGREGA ÁB, et al. Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells[J]. Gut, 2020, 69(5): 920-932. DOI: 10.1136/gutjnl-2019-318372.
[26]	CHENG C, HUANG C, MA TT, et al. New surprises of suppressor of cytokine signalling in liver fibrosis[J]. Expert Opin Ther Targets, 2014, 18(4): 415-426. DOI: 10.1517/14728222.2014.885953.
[27]	YOSHIDA T, OGATA H, KAMIO M, et al. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis[J]. J Exp Med, 2004, 199(12): 1701-1707. DOI: 10.1084/jem.20031675.
[28]	JAMHIRI I, SHAHIN K, KHODABANDEH Z, et al. Recombinant NS3 protein induced expression of immune modulatory elements in hepatic stellate cells during its fibrotic activity[J]. Viral Immunol, 2018, 31(8): 575-582. DOI: 10.1089/vim.2018.0018.
[29]	KIM HY, JHUN JY, CHO ML, et al. Interleukin-6 upregulates Th17 response via mTOR/STAT3 pathway in acute-on-chronic hepatitis B liver failure[J]. J Gastroenterol, 2014, 49(8): 1264-1273. DOI: 10.1007/s00535-013-0891-1.
[30]	LI Y, HAN MF, LI WN, et al. SOCS3 expression correlates with severity of inflammation in mouse hepatitis virus strain 3-induced acute liver failure and HBV-ACLF[J]. J Huazhong Univ Sci Technolog Med Sci, 2014, 34(3): 348-353. DOI: 10.1007/s11596-014-1281-5.
[31]	LI SS, YANG M, CHEN YP, et al. Dendritic cells with increased expression of suppressor of cytokine signaling 1(SOCS1) gene ameliorate lipopolysaccharide/d-galactosamine-induced acute liver failure[J]. Mol Immunol, 2018, 101: 10-18. DOI: 10.1016/j.molimm.2018.05.016.
[32]	ZHANG JJ, FAN YC, ZHAO ZH, et al. Prognoses of patients with acute-on-chronic hepatitis B liver failure are closely associated with altered SOCS1 mRNA expression and cytokine production following glucocorticoid treatment[J]. Cell Mol Immunol, 2014, 11(4): 396-404. DOI: 10.1038/cmi.2014.23.
[33]	MA HC, WANG X, WU MN, et al. Interleukin-10 contributes to therapeutic effect of mesenchymal stem cells for acute liver failure via signal transducer and activator of transcription 3 signaling pathway[J]. Chin Med J (Engl), 2016, 129(8): 967-975. DOI: 10.4103/0366-6999.179794.
[34]	YIN JP, YUE ZC, ZHUO SY. STAT3: A key molecule in the progression of liver cancer mediated by chronic inflammation[J]. J Clin Hepatol, 2020, 36(4): 948-952. DOI: 10.3969/j.issn.1001-5256.2020.04.054. 音金萍, 岳紫晨, 卓少元. STAT3: 慢性炎症介导肝癌进程的关键分子[J]. 临床肝胆病杂志, 2020, 36(4): 948-952. DOI: 10.3969/j.issn.1001-5256.2020.04.054.
[35]	LI TF, SU CY, HUANG G, et al. IL-6 suppresses CCR7 expression in human monocyte-derived dendritic cells via STAT3 pathway[J]. J Third Mil Med Univ, 2015, 37(8): 751-756.
[36]	XIONG S, WANG R, CHEN Q, et al. Cancer-associated fibroblasts promote stem cell-like properties of hepatocellular carcinoma cells through IL-6/STAT3/Notch signaling[J]. Am J Cancer Res, 2018, 8(2): 302-316.
[37]	YIN Z, MA T, LIN Y, et al. IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma[J]. J Cell Biochem, 2018, 119(11): 9419-9432. DOI: 10.1002/jcb.27259.
[38]	WANG B, LIU T, WU JC, et al. STAT3 aggravates TGF-β1-induced hepatic epithelial-to-mesenchymal transition and migration[J]. Biomed Pharmacother, 2018, 98: 214-221. DOI: 10.1016/j.biopha.2017.12.035.
[39]	CHEN G, WANG H, XIE S, et al. STAT1 negatively regulates hepatocellular carcinoma cell proliferation[J]. Oncol Rep, 2013, 29(6): 2303-2310. DOI: 10.3892/or.2013.2398.
[40]	JIN Y, SUN Z, GENG J, et al. IL-21 reinvigorates exhausted natural killer cells in patients with HBV-associated hepatocellular carcinoma in STAT1-depedent pathway[J]. Int Immunopharmacol, 2019, 70: 1-8. DOI: 10.1016/j.intimp.2019.02.007.
[41]	GAO MD, ZHANG YH, ZHAO Y. Role of signal transduction and transcription factors STAT1 and STAT3 in the pathogen-esis of hepatocellular carcinoma and liver failure[J]. J Clin Hepatol, 2018, 34(9): 2017-2020. DOI: 10.3969/j.issn.1001-5256.2018.09.040 高梦丹, 张永宏, 赵艳. STAT1与STAT3在肝细胞癌及肝衰竭发病机制中的作用[J]. 临床肝胆病杂志, 2018, 34(9): 2017-2020. DOI: 10.3969/j.issn.1001-5256.2018.09.040.
[42]	KALTENECKER D, THEMANNS M, MUELLER KM, et al. Hepatic growth hormone - JAK2 - STAT5 signalling: Metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression[J]. Cytokine, 2019, 124: 154569. DOI: 10.1016/j.cyto.2018.10.010.
[43]	WANG X, LIAO X, YU T, et al. Analysis of clinical significance and prospective molecular mechanism of main elements of the JAK/STAT pathway in hepatocellular carcinoma[J]. Int J Oncol, 2019, 55(4): 805-822. DOI: 10.3892/ijo.2019.4862.
[44]	ZHANG X, WANG J, CHENG J, et al. An integrated analysis of SOCS1 down-regulation in HBV infection-related hepatocellular carcinoma[J]. J Viral Hepat, 2014, 21(4): 264-271. DOI: 10.1111/jvh.12137.
[45]	KHAN M, GHOSH A, VARIYA B, et al. Hepatocyte growth control by SOCS1 and SOCS3[J]. Cytokine, 2019, 121: 154733. DOI: 10.1016/j.cyto.2019.154733.
[46]	YANG Z, ZHU H, ZHANG L, et al. DNA methylation of SOCS1/2/3 predicts hepatocellular carcinoma recurrence after liver transplantation[J]. Mol Biol Rep, 2020, 47(3): 1773-1782. DOI: 10.1007/s11033-020-05271-3.
[47]	CUI M, SUN J, HOU J, et al. The suppressor of cytokine signaling 2 (SOCS2) inhibits tumor metastasis in hepatocellular carcinoma[J]. Tumour Biol, 2016, 37(10): 13521-13531. DOI: 10.1007/s13277-016-5215-7.
[48]	ZHANG M, LIU S, CHUA MS, et al. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway[J]. Cell Death Dis, 2019, 10(8): 612. DOI: 10.1038/s41419-019-1856-y.